Table 2.
Demographics and clinicopathological characteristics of the external validation and SEER cohort.
| Variables | External cohort (N = 215) |
SEER cohort (N = 961) |
P-value |
|---|---|---|---|
| Age | 0.226 | ||
| ≤ 35 | 101 (47.0%) | 408 (42.5%) | |
| > 35 | 114 (53.0%) | 553 (57.5%) | |
| Gender | 0.854 | ||
| Male | 105 (48.8%) | 476 (49.5%) | |
| Female | 110 (51.2%) | 485 (50.5%) | |
| Race | < 0.001 | ||
| White | 0 (0%) | 633 (65.9%) | |
| Black | 0 (0%) | 140 (14.6%) | |
| Other1 | 215 (100%) | 188 (19.6%) | |
| Marital status | < 0.001 | ||
| Married | 188 (87.4%) | 501 (52.1%) | |
| Others2 | 27 (12.6%) | 460 (47.9%) | |
| Side | < 0.001 | ||
| Left | 73 (34.0%) | 371 (38.6%) | |
| Right | 84 (39.1%) | 520 (54.1%) | |
| Bilateral | 58 (27.0%) | 70 (7.3%) | |
| Primary site | 0.333 | ||
| Main bronchus | 12 (5.6%) | 37 (3.9%) | |
| Upper lobe | 93 (43.3%) | 387 (40.3% | |
| Middle lobe | 15 (7.0%) | 52 (5.4%) | |
| Lower lobe | 59 (27.4%) | 262 (27.3%) | |
| Overlapping lesion | 3 (1.4%) | 18 (1.9%) | |
| Lung NOS | 33 (15.3%) | 205 (21.3%) | |
| Histological type | < 0.001 | ||
| Adenocarcinoma | 205 (95.3%) | 705 (73.4%) | |
| Squamous | 7 (3.3%) | 181 (18.8%) | |
| Others3 | 3 (1.4%) | 75 (7.8%) | |
| T stage | < 0.001 | ||
| T0 | 0 (0%) | 9 (0.9%) | |
| T1 | 46 (21.4%) | 108 (11.2%) | |
| T2 | 50 (23.3%) | 204 (21.2%) | |
| T3 | 44 (20.5%) | 248 (25.8%) | |
| T4 | 75 (34.9%) | 392 (40.8%) | |
| N stage | < 0.001 | ||
| N0 | 13 (6.0%) | 178 (18.5%) | |
| N1 | 47 (21.9%) | 90 (9.4%) | |
| N2 | 34 (15.8%) | 401 (41.7%) | |
| N3 | 121 (56.3%) | 292 (30.4%) | |
| M stage | < 0.001 | ||
| M1a | 73 (34.0%) | 208 (21.6%) | |
| M1b | 142 (66.0%) | 725 (75.4%) | |
| M1NOS | 0 (0%) | 28 (2.9%) | |
| Bone metastasis | 0.013 | ||
| No | 96 (44.7%) | 519 (54.0%) | |
| Yes | 119 (55.3%) | 442 (46.0%) | |
| Brain metastasis | 0.465 | ||
| No | 147 (68.4%) | 632 (65.8%) | |
| Yes | 68 (31.6%) | 329 (34.2%) | |
| Liver metastasis | 0.410 | ||
| No | 175 (81.4%) | 758 (78.9%) | |
| Yes | 40 (18.6%) | 203 (21.1%) | |
| Lung metastasis | 0.915 | ||
| No | 139 (64.7%) | 625 (65.0%) | |
| Yes | 76 (35.3%) | 336 (35.0%) | |
| Chemotherapy | 0.007 | ||
| No | 55 (25.6%) | 169 (17.6%) | |
| Yes | 160 (74.4%) | 792 (82.4%) | |
| Radiotherapy | < 0.001 | ||
| No | 156 (72.6%) | 450 (46.8%) | |
| Yes | 59 (27.4%) | 511 (53.2%) | |
| Immunotherapy | NA | ||
| No | 195 (90.7%) | NA | |
| Yes | 20 (9.3%) | NA | |
| Targeted therapy | NA | ||
| No | 78 (36.3%) | NA | |
| Yes | 137 (63.7%) | NA |
Other1: American Indian, AK Native, Asian or Pacific Islander.
Others2: Unmarried or Domestic Partner, Single (never married), Widowed, Divorced, Separated
Others3: Mucoepidermoid carcinoma, Mucinous adenocarcinoma, Synovial sarcoma.